Cailian Liu Selected Research

Autoantigens

4/2009	Immune rejection of mouse tumors expressing mutated self.
5/2006	Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cailian Liu Research Topics

Disease

23	Neoplasms (Cancer) 01/2024 - 05/2006
11	Melanoma (Melanoma, Malignant) 01/2024 - 05/2006
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2018
3	Experimental Melanoma 10/2021 - 05/2006
2	Lung Neoplasms (Lung Cancer) 01/2024 - 01/2018
1	Inflammation (Inflammations) 01/2024
1	Ascites 12/2021
1	Pleural Effusion (Pleural Effusions) 12/2021
1	Disease Progression 10/2020
1	Urinary Bladder Neoplasms (Bladder Cancer) 06/2018
1	Infections 12/2012
1	Lymphopenia (Lymphocytopenia) 10/2012
1	Fibrosarcoma 04/2009
1	Herpes Simplex 04/2008

Drug/Important Bio-Agent (IBA)

7	Immune Checkpoint InhibitorsIBA 01/2023 - 12/2014
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 05/2006
4	VaccinesIBA 01/2024 - 05/2006
4	AntigensIBA 01/2023 - 04/2008
4	AntibodiesIBA 01/2019 - 12/2014
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2023 - 04/2008
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2021 - 04/2009
3	GlucocorticoidsIBA 10/2021 - 04/2009
3	DNA (Deoxyribonucleic Acid)IBA 04/2008 - 05/2006
2	eprenetapoptIBA 01/2024 - 01/2022
2	Immunomodulating AgentsIBA 01/2024 - 06/2018
2	PhosphatidylserinesIBA 12/2021 - 12/2021
2	IpilimumabIBA 01/2015 - 12/2014
2	Monoclonal AntibodiesIBA 05/2010 - 04/2009
2	EpitopesIBA 04/2009 - 05/2006
2	Monophenol Monooxygenase (Tyrosinase)IBA 04/2009 - 05/2006
2	AutoantigensIBA 04/2009 - 05/2006
2	Peptides (Polypeptides)IBA 04/2009 - 05/2006
1	InterferonsIBA 01/2024
1	Melanoma-Specific AntigensIBA 01/2023
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2023
1	pembrolizumabIBA 01/2022
1	Alkylating AgentsIBA 10/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021
1	EnzymesIBA 11/2020
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 11/2020
1	Tryptophan (L-Tryptophan)FDA Link 11/2020
1	Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA 11/2020
1	Programmed Cell Death 1 ReceptorIBA 11/2016
1	B7-H1 AntigenIBA 11/2016
1	Biomarkers (Surrogate Marker)IBA 01/2015
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2015
1	tremelimumabIBA 12/2014
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2014
1	raf KinasesIBA 04/2014
1	VemurafenibIBA 04/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2013
1	Transcription Factors (Transcription Factor)IBA 11/2013
1	CytokinesIBA 10/2012
1	Immunoglobulin G (IgG)IBA 05/2010
1	Pseudomonas aeruginosa Exotoxin AIBA 04/2008
1	OMPA outer membrane proteinsIBA 04/2008
1	dopachrome isomeraseIBA 05/2006
1	LigandsIBA 05/2006
1	tyrosinase-related protein-1IBA 05/2006
1	Differentiation AntigensIBA 05/2006
1	DNA VaccinesIBA 05/2006

Therapy/Procedure

10	Immunotherapy 01/2024 - 04/2008
6	Therapeutics 01/2023 - 01/2018
3	Ligation 11/2013 - 05/2006
1	Radiotherapy 12/2021
1	Hematopoietic Stem Cell Transplantation 12/2012
1	Drug Therapy (Chemotherapy) 10/2012